423 related articles for article (PubMed ID: 8806005)
41. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
Grese TA; Cho S; Finley DR; Godfrey AG; Jones CD; Lugar CW; Martin MJ; Matsumoto K; Pennington LD; Winter MA; Adrian MD; Cole HW; Magee DE; Phillips DL; Rowley ER; Short LL; Glasebrook AL; Bryant HU
J Med Chem; 1997 Jan; 40(2):146-67. PubMed ID: 9003514
[TBL] [Abstract][Full Text] [Related]
42. Clinical effects of raloxifene hydrochloride in women.
Khovidhunkit W; Shoback DM
Ann Intern Med; 1999 Mar; 130(5):431-9. PubMed ID: 10068418
[TBL] [Abstract][Full Text] [Related]
43. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models.
Ke HZ; Paralkar VM; Grasser WA; Crawford DT; Qi H; Simmons HA; Pirie CM; Chidsey-Frink KL; Owen TA; Smock SL; Chen HK; Jee WS; Cameron KO; Rosati RL; Brown TA; Dasilva-Jardine P; Thompson DD
Endocrinology; 1998 Apr; 139(4):2068-76. PubMed ID: 9528995
[TBL] [Abstract][Full Text] [Related]
44. Estrogenic properties of raloxifene, but not tamoxifen, on D2 and D3 dopamine receptors in the rat forebrain.
Landry M; Lévesque D; Di Paolo T
Neuroendocrinology; 2002 Oct; 76(4):214-22. PubMed ID: 12411738
[TBL] [Abstract][Full Text] [Related]
45. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
[TBL] [Abstract][Full Text] [Related]
46. Comparative effects of estrogen and raloxifene on B lymphopoiesis and bone loss induced by sex steroid deficiency in mice.
Onoe Y; Miyaura C; Ito M; Ohta H; Nozawa S; Suda T
J Bone Miner Res; 2000 Mar; 15(3):541-9. PubMed ID: 10750569
[TBL] [Abstract][Full Text] [Related]
47. Effects of two novel selective estrogen receptor modulators, raloxifene, tamoxifen, and ethinyl estradiol on the uterus, vagina and breast in ovariectomized cynomolgus monkeys (Macaca fascicularis).
Sikoski P; Register TC; Lees CJ; Lundeen S; Hutchison J; Brown KH; Cline JM
Am J Obstet Gynecol; 2007 Jan; 196(1):75.e1-7. PubMed ID: 17240242
[TBL] [Abstract][Full Text] [Related]
48. Changes in 5-HT1A receptor binding and G-protein activation in the rat brain after estrogen treatment: comparison with tamoxifen and raloxifene.
Le Saux M; Di Paolo T
J Psychiatry Neurosci; 2005 Mar; 30(2):110-7. PubMed ID: 15798786
[TBL] [Abstract][Full Text] [Related]
49. Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats.
Sato M; Kim J; Short LL; Slemenda CW; Bryant HU
J Pharmacol Exp Ther; 1995 Mar; 272(3):1252-9. PubMed ID: 7891341
[TBL] [Abstract][Full Text] [Related]
50. A comparative study of the effects of genistein, estradiol and raloxifene on the murine skeletal system.
Sliwiński L; Folwarczna J; Nowińska B; Cegieła U; Pytlik M; Kaczmarczyk-Sedlak I; Trzeciak H; Trzeciak HI
Acta Biochim Pol; 2009; 56(2):261-70. PubMed ID: 19401787
[TBL] [Abstract][Full Text] [Related]
51. Raloxifene.
Balfour JA; Goa KL
Drugs Aging; 1998 Apr; 12(4):335-41; discussion 342. PubMed ID: 9571395
[TBL] [Abstract][Full Text] [Related]
52. Estrogenic activity of tamoxifen and raloxifene on rat brain AMPA receptors.
Cyr M; Morissette M; Landry M; Di Paolo T
Neuroreport; 2001 Mar; 12(3):535-9. PubMed ID: 11234759
[TBL] [Abstract][Full Text] [Related]
53. Comparative study of the short-term effects of a novel selective estrogen receptor modulator, ospemifene, and raloxifene and tamoxifen on rat uterus.
Zheng H; Kangas L; Härkönen PL
J Steroid Biochem Mol Biol; 2004 Feb; 88(2):143-56. PubMed ID: 15084346
[TBL] [Abstract][Full Text] [Related]
54. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis.
Hernández E; Valera R; Alonzo E; Bajares-Lilue M; Carlini R; Capriles F; Martinis R; Bellorin-Font E; Weisinger JR
Kidney Int; 2003 Jun; 63(6):2269-74. PubMed ID: 12753317
[TBL] [Abstract][Full Text] [Related]
55. Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia.
Evans GL; Bryant HU; Magee DE; Turner RT
Endocrinology; 1996 Oct; 137(10):4139-44. PubMed ID: 8828469
[TBL] [Abstract][Full Text] [Related]
56. Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats.
Wang XN; Simmons HA; Salatto CT; Cosgrove PG; Thompson DD
Menopause; 2006; 13(4):609-20. PubMed ID: 16837883
[TBL] [Abstract][Full Text] [Related]
57. The potential anti-osteoporotic effect of exercise-induced increased preptin level in ovariectomized rats.
Abdelfattah Abulfadle K; Refaat Abdelkader Atia R; Osama Mohammed H; Saad Ramadan R; Mohammed NA
Anat Sci Int; 2023 Jan; 98(1):22-35. PubMed ID: 35507276
[TBL] [Abstract][Full Text] [Related]
58. Effect of chronic estradiol, tamoxifen or raloxifene treatment on serotonin 5-HT1A receptor.
Landry M; Di Paolo T
Brain Res Mol Brain Res; 2003 Apr; 112(1-2):82-9. PubMed ID: 12670705
[TBL] [Abstract][Full Text] [Related]
59. A comparative study of the actions of tamoxifen, estrogen and progesterone in the ovariectomized rat.
Kalu DN; Salerno E; Liu CC; Echon R; Ray M; Garza-Zapata M; Hollis BW
Bone Miner; 1991 Nov; 15(2):109-23. PubMed ID: 1764629
[TBL] [Abstract][Full Text] [Related]
60. Chronic estrogenic drug treatment increases preproenkephalin mRNA levels in the rat striatum and nucleus accumbens.
Le Saux M; Di Paolo T
Psychoneuroendocrinology; 2005 Apr; 30(3):251-60. PubMed ID: 15511599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
